Does Decipher provide any additional value in determining whether patients with metastatic hormone sensitive prostate cancer should receive chemotherapy?

Docetaxel has been part of the treatment paradigm for metastatic androgen pathway inhibitor-sensitive prostate cancer since the CHAARTED and STAMPEDE trials showed its value in addition to standard ADT, particularly in patients with "high volume" disease based on clinical features/lesion number from...

Current clinical decision-making for docetaxel in mHSPC remains based primarily on disease volume (CHAARTED criteria) and patient fitness. While emerging evidence suggests that DECIPHER scores can predict which mHSPC patients benefit from adding docetaxel, particularly those with high scores (>0.8–0...